Table 5.
Coefficient Estimates for the Interactions with Time in Modeling Proteinuria Risk over Observation Period in Patients with Sickle Cell Disease.
| HbSS/HbSβ0-Thalassemia (Severe genotypes) | ||
|---|---|---|
| Estimate (SE) | P | |
| Hemoglobin | −0.046 (0.032) | 0.1 |
| LDH | 0.000032 (0.000084) | 0.7 |
| Reticulocyte count | 0.00041 (0.00039) | 0.3 |
| Hemoglobin F | −0.011 (0.014) | 0.4 |
| WBC count | −0.012 (0.014) | 0.4 |
| Ferritin | 0.000021 (0.000052) | 0.7 |
| Total bilirubin | 0.012 (0.024) | 0.6 |
| Direct bilirubin | 1.89 (1.57) | 0.2 |
| Indirect bilirubin | 0.041 (0.058) | 0.5 |
| Baseline eGFR | −0.00001 (0.0015) | 0.9 |
| Hemoglobinuria | −0.27 (0.22) | 0.2 |
| Urine specific gravity | −32.68 (21.78) | 0.1 |
| Systolic BP | −0.0028 (0.0028) | 0.3 |
| Diastolic BP | −0.0049 (0.0030) | 0.1 |
| Weight | −0.0067 (0.0032) | 0.04 |
| Diabetes mellitus | −0.33 (0.24) | 0.2 |
| History of stroke | 0.044 (0.12) | 0.7 |
| History of acute chest syndrome | 0.45 (0.24) | 0.06 |
| History of avascular necrosis | 0.079 (0.10) | 0.4 |
| History of leg ulcers | 0.0069 (0.10) | 0.9 |
| ACEi/ARB therapy | −0.11 (0.098) | 0.3 |
| Hydroxyurea therapy | −0.13 (0.085) | 0.1 |
| Ongoing need for RBC transfusion | −0.41 (0.65) | 0.5 |
Estimates expressed log-odds of proteinuria over time; for continuous covariates, estimate is per 1-unit increase.
Results from minimally adjusted (age and sex) generalized linear mixed effects model with random intercept and random time effect for each covariate.
ACEi = Angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker; RBC, _______; LDH, _____; WBC, _____; BP, blood pressure; eGFR, estimated glomerular filtration rate; SE, _____.